Chemistry:Radiprodil
From HandWiki
Radiprodil (INN; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures.[1][2][3] It is taken orally.[1] The drug is being developed by GRIN Therapeutics.[1] As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures.[1] The drug was first described in the scientific literature by 2003.[4]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "GRIN Therapeutics". 28 December 2025. https://adisinsight.springer.com/drugs/800069843.
- ↑ "Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome". Annals of Clinical and Translational Neurology 7 (3): 343–352. March 2020. doi:10.1002/acn3.50998. PMID 32106360.
- ↑ "GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors". Neuropharmacology 123: 322–331. September 2017. doi:10.1016/j.neuropharm.2017.05.017. PMID 28533163.
- ↑ "RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models.". Society for Neuroscience. Washington, DC. 2003. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner.. https://scholar.google.com/scholar?cluster=1937207076977424379.
 |  |
